KRAS Status and Outcome of Liver Resection…

KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab

The prognostic value of KRAS mutation in patients with colorectal cancer liver metastases (CLM) receiving neoadjuvant chemotherapy following liver resection was investigated. The response rate to neoaduvant therapy was similar in patients with aKRAS mutation and those with the wild‐type gene. KRAS mutation had a negative prognostic effect on recurrence‐free survival.

Br J Surg 2012;99(11):1575-82

OnSurg thanks the editors at School of Surgery for making their current surgical literature summaries available to the world. School of Surgery tweets at @schoolofsurgery and maintains a Facebook fan page here.

Post Tagged with


Related Posts